EU/3/16/1822 - orphan designation for treatment of interstitial cystitis
pentosan polysulfate sodium
Orphan
Human
Overview
On 12 January 2017, orphan designation (EU/3/16/1822) was granted by the European Commission to Kyoto tech Limited, United Kingdom, for pentosan polysulfate sodium for the treatment of interstitial cystitis.
The sponsorship was transferred to HV-Polysaccharides GmbH & Co. KG, Germany, in June 2017.
Interstitial cystitis is a long-term inflammatory condition of the bladder. The cause of the condition is unknown and a diagnosis is normally made after other likely causes such as infection have been ruled out. Symptoms include pain in the pelvic area, increased frequency of urination, and pain while urinating.
Interstitial cystitis is debilitating in the long term due to the associated pain and discomfort and the increased urinary frequency.
At the time of designation, interstitial cystitis affected approximately 2 in 10,000 people in the European Union (EU). This was equivalent to a total of around 103,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 513,700,000 (Eurostat 2016).
At the time of designation, no satisfactory methods for treating interstitial cystitis were authorised in the EU. Painkillers were used to manage the pain. Pentosan polysulfate sodium was authorised in some countries to relieve pain and discomfort in patients with interstitial cystitis.
It is thought that in interstitial cystitis defects may occur in the protective layer of molecules called glycosaminoglycans (or GAGs) in the lining of the bladder. This medicine, pentosan polysulfate sodium, is very similar to GAGs and it is expected to work by attaching to and repairing the defective GAG layer. This is expected to protect bladder cells from irritating substances in the urine, thereby improving the symptoms of the disease.
As pentosan polysulfate sodium is a well-known substance, the sponsor provided data in patients from the published literature to support its application for orphan designation.
At the time of submission of the application for orphan designation, pentosan polysulfate sodium was authorised in several countries outside the EU for treating interstitial cystitis.
At the time of submission, the medicine was not authorised anywhere in the EU for interstitial cystitis. Orphan designation of the medicine had been granted in the EU and United States for this condition.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 8 December 2016 recommending the granting of this designation.
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
Key facts
- Active substance
- pentosan polysulfate sodium
- Medicine name
- -
- Intended use
- Treatment of interstitial cystitis
- Orphan designation status
- Positive
- EU designation number
- EU/3/16/1822
- Date of designation
- Sponsor
HV-Polysaccharides GmbH & Co. KG
Am Amselberg 1
07751 Bucha
Germany
Tel. +49 151 260 557 36
E-mail: regulatory-affairs@hv-polysaccharides.de
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
EMA list of opinions on orphan medicinal product designation
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: